Ítem
Solo Metadatos

Intravitreal bevacizumab (Avastin®) for diabetic retinopathy at 24-months: The 2008 Juan Verdaguer-planas lecture

dc.creatorArevalo J.F.spa
dc.creatorSanchez J.G.spa
dc.creatorLasave A.F.spa
dc.creatorWu L.spa
dc.creatorMaia M.spa
dc.creatorBonafonte S.spa
dc.creatorBrito M.spa
dc.creatorAlezzandrini A.A.spa
dc.creatorRestrepo N.spa
dc.creatorBerrocal M.H.spa
dc.creatorSaravia M.spa
dc.creatorFarah M.E.spa
dc.creatorFromow-Guerra J.spa
dc.creatorMorales-Canton V.spa
dc.creatorWu L.spa
dc.creatorEspinoza J.V.spa
dc.creatorMaia M.spa
dc.creatorAggio F.B.spa
dc.creatorQuiroz-Mercado H.spa
dc.creatorGuerrero-Naranjo J.L.spa
dc.creatorRodriguez F.J.spa
dc.creatorInfante R.spa
dc.creatorMedina D.spa
dc.creatorCruz-Villegas V.spa
dc.creatorGraue-Wiechers F.spa
dc.creatorLozano-Rechy D.spa
dc.creatorRobledo V.spa
dc.creatorRodriguez-Loaiza J.L.spa
dc.creatorRoca J.A.spa
dc.creatorReategui G.spa
dc.creatorSaravia M.J.spa
dc.creatorMartinez-Cartier M.spa
dc.creatorAvila M.spa
dc.creatorCardillo J.spa
dc.creatorCosta R.A.spa
dc.creatorVerdaguer J.spa
dc.creatorCarpentier C.spa
dc.creatorVerdaguer J.I.spa
dc.creatorFilsecker D.L.spa
dc.creatorSepúlveda G.spa
dc.creatorSanchez F.spa
dc.creatorMarini C.spa
dc.creatorGarcia B.spa
dc.creatorPan-American Collaborative Retina Study Group (PACORES)spa
dc.creator.OrganizationalPan-American Collaborative Retina Study Group (PACORES)
dc.date.accessioned2020-05-26T00:05:31Z
dc.date.available2020-05-26T00:05:31Z
dc.date.created2010spa
dc.description.abstractDiabetic retinopathy (DR) remains the major threat to sight in the working age population. Diabetic macular edema (DME) is a manifestation of DR that produces loss of central vision. Proliferative diabetic retinopathy (PDR) is a major cause of visual loss in diabetic patients. In PDR, the growth of new vessels is thought to occur as a result of vascular endothelial growth factor (VEGF) release into the vitreous cavity as a response to ischemia. Furthermore, VEGF increases vessel permeability leading to deposition of proteins in the interstitium that facilitate the process of angiogenesis and macular edema. This review demonstrates multiple benefits of intravitreal bevacizumab (IVB) on DR including DME and PDR at 24 months of follow up. The results indicate that IVB injections may have a beneficial effect on macular thickness and visual acuity (VA) in diffuse diabetic macular edema. Therefore, in the future this new therapy could replace or complement focal/grid laser photocoagulation in DME. In PDR, this new option could be an adjuvant agent to pan-retina photocoagulation so that more selective therapy may be applied. In addition, we report a series of patients in which tractional retinal detachment developed or progressed after adjuvant preoperative IVB in severe PDR. © 2010 Bentham Science Publishers Ltd.eng
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://doi.org/10.2174/157339910793360842
dc.identifier.issn15733998
dc.identifier.urihttps://repository.urosario.edu.co/handle/10336/23801
dc.language.isoengspa
dc.publisherBentham Science Publishers B.V.spa
dc.relation.citationEndPage322
dc.relation.citationIssueNo. 5
dc.relation.citationStartPage313
dc.relation.citationTitleCurrent Diabetes Reviews
dc.relation.citationVolumeVol. 6
dc.relation.ispartofCurrent Diabetes Reviews, ISSN:15733998, Vol.6, No.5 (2010); pp. 313-322spa
dc.relation.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-79952118856&doi=10.2174%2f157339910793360842&partnerID=40&md5=2dac37deaa9d506d3767e6658ebeb9acspa
dc.rights.accesRightsinfo:eu-repo/semantics/openAccess
dc.rights.accesoAbierto (Texto Completo)spa
dc.source.instnameinstname:Universidad del Rosariospa
dc.source.reponamereponame:Repositorio Institucional EdocURspa
dc.subject.keywordBevacizumabspa
dc.subject.keywordAngiogenesis inhibitorspa
dc.subject.keywordBevacizumabspa
dc.subject.keywordMonoclonal antibodyspa
dc.subject.keywordArticlespa
dc.subject.keywordDiabetic macular edemaspa
dc.subject.keywordDiabetic retinopathyspa
dc.subject.keywordDisease severityspa
dc.subject.keywordFollow upspa
dc.subject.keywordHumanspa
dc.subject.keywordLaser coagulationspa
dc.subject.keywordMacular thicknessspa
dc.subject.keywordPriority journalspa
dc.subject.keywordProliferative diabetic retinopathyspa
dc.subject.keywordRetina detachmentspa
dc.subject.keywordTreatment outcomespa
dc.subject.keywordVisual acuityspa
dc.subject.keywordAdultspa
dc.subject.keywordAgedspa
dc.subject.keywordAnimalspa
dc.subject.keywordArticlespa
dc.subject.keywordCell proliferationspa
dc.subject.keywordDiabetic retinopathyspa
dc.subject.keywordDrug effectspa
dc.subject.keywordEvaluationspa
dc.subject.keywordFemalespa
dc.subject.keywordIntravitreal drug administrationspa
dc.subject.keywordMalespa
dc.subject.keywordMiddle agedspa
dc.subject.keywordOptical coherence tomographyspa
dc.subject.keywordRetina macula edemaspa
dc.subject.keywordRetrospective studyspa
dc.subject.keywordTimespa
dc.subject.keywordAdultspa
dc.subject.keywordAgedspa
dc.subject.keywordAngiogenesis inhibitorsspa
dc.subject.keywordAnimalsspa
dc.subject.keywordAntibodieseng
dc.subject.keywordCell proliferationspa
dc.subject.keywordDiabetic retinopathyspa
dc.subject.keywordFemalespa
dc.subject.keywordFollow-up studiesspa
dc.subject.keywordHumansspa
dc.subject.keywordIntravitreal injectionsspa
dc.subject.keywordMacular edemaspa
dc.subject.keywordMalespa
dc.subject.keywordMiddle agedspa
dc.subject.keywordRetrospective studiesspa
dc.subject.keywordTime factorsspa
dc.subject.keywordTomographyeng
dc.subject.keywordDiffuse diabetic macular edemaspa
dc.subject.keywordIntravitreal bevacizumabspa
dc.subject.keywordPanretinal photocoagulationspa
dc.subject.keywordProliferative diabetic retinopathyspa
dc.subject.keywordTractional retinal detachmentspa
dc.subject.keywordVascular endothelial growth factorspa
dc.titleIntravitreal bevacizumab (Avastin®) for diabetic retinopathy at 24-months: The 2008 Juan Verdaguer-planas lecturespa
dc.typearticleeng
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersion
dc.type.spaArtículospa
Archivos
Colecciones